CliffBio
small molecule

ARYNTA

LISDEXAMFETAMINE DIMESYLATE

Loss of exclusivityAugust 2040latest FDA-listed patent expiry
CompanyAzurity Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameARYNTA
Active ingredientLISDEXAMFETAMINE DIMESYLATE
Strength10MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalJune 2025
Marketing statusRX

Listed patents

PatentExpiresType
11576878August 2040product
12433859April 2040product
12582620April 2040product

More from Azurity Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ARYNTA patent cliff — loss of exclusivity August 2040 | CliffBio